Liraglutide Shows Promise

 

One of the most common occurrences in medical research is to attempt to use existing treatments for other conditions. A good example of that comes from the studies of liraglutide in weight loss, which have been gaining momentum for the last couple of years. That is why we were not surprised to hear about an additional study supporting the idea of considering liraglutide for weight loss.

Liraglutide is the active ingredient in the diabetes treatment called Victoza, and works by aiding the production of insulin. Whilst Victoza comes in doses of 1.2mg and 1.8 mg, it appears that 3.0mg has been projected as the best dose to aid weight loss (assuming that the patients take the treatment in combination with exercise and healthy diet).

The results from the most recent trial were recently presented at the European Congress on Obesity and appear to have been met favourably by the attendees. The placebo-controlled study included a total of 3731 adults with an average age of 45. All the participants were considered obese or overweight, and although 61% of the participants could have been considered pre-diabetic – none met the diagnosis of type 2 diabetes. Regardless of the group, all participants undertook a diet of 500 calories lower than a normal diet and took part in physical activity five days a week.  The main findings suggested that almost 75% of the treatment group (who had been taking Victoza) lost 5% of their body weight. In contrast to that, only 27% of the participants in the placebo group lost 5% of their body weight. More information can be found here.

Based on these findings and findings from previous trials, it should not come as a surprise that the manufacturers are seeking approval from the FDA to market liraglutide for treatment of weight loss. However, it will take some time before the treatment is out on the market.

You can read more about the latest developments with new weight loss medications at Reducing Fat, a website dedicated to publishing research in this area.